Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies
In the phase 3 CheckMate 214 trial, ipilimumab plus nivolumab demonstrated improved overall survival and objective response rates compared with sunitinib for patients with advanced RCC.
This review outlines pharmacologic management of renal cell carcinoma, focusing on immunotherapy and targeted therapy according to current NCCN guidelines and discusses dosing, administration, safety, and ongoing clinical trials.
Advancing therapeutic knowledge improves outcomes for patients with advanced renal cell carcinoma.
Evidence level: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Related signals
- Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy
- A Review of Immunotherapy in Renal Cell Carcinoma: Current Landscape and Future Directions
- EAU 2025: State-of-the-Art Lecture: Neoadjuvant Strategies in Locally Advanced Renal Cancer
- Early detection of renal cell carcinoma: a novel cell-free DNA fragmentomics‑based liquid biopsy assay
- Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)